Drug-microbiota interactions: an emerging priority for precision medicine

Individual variability in drug response(IVDR)can be a major cause of adverse drug reactions(ADRs)and prolonged therapy,resulting in a substantial health and economic burden.Despite extensive research in pharmacogenomics regarding the impact of individual genetic background on pharmacokinetics(PK)and pharmacodynamics(PD),genetic diversity explains only a limited proportion of IVDR.The role of gut microbiota,also known as the second genome,and its metabolites in modulating therapeutic outcomes in human diseases have been highlighted by recent studies.Consequently,the burgeoning field of pharmacomicrobiomics aims to explore the correlation between microbiota variation and IVDR or ADRs.This review presents an up-to-date overview of the intricate interactions between gut microbiota and classical therapeutic agents for human systemic diseases,including cancer,cardiovascular diseases(CVDs),endocrine diseases,and others.We summarise how microbiota,directly and indirectly,modify the absorption,distribution,metabolism,and excretion(ADME)of drugs.Conversely,drugs can also modulate the composition and function of gut microbiota,leading to changes in microbial metabolism and immune response.We also discuss the practical challenges,strategies,and opportunities in this field,emphasizing the critical need to develop an innovative approach to multi-omics,integrate various data types,including human and microbiota genomic data,as well as translate lab data into clinical practice.To sum up,pharmacomicrobiomics represents a promising avenue to address IVDR and improve patient outcomes,and further research in this field is imperative to unlock its full potential for precision medicine.